“In the long term, as more and more innovative products continue to be launched using inputs from many nations, a new type of pricing method may need to be developed in Japan.”
The Asia Group (TAG) has released an update to its 2023 white paper “Observations on Drug Pricing and Innovation in Japan” which analyzes the outstanding policy challenge of the “zero co-factor” rule under the cost-based price calculation method, which continues to undermine the Japanese government’s efforts to restore the country’s drug discovery capabilities and create a robust pharmaceutical industry ecosystem.
He argued that Japan’s drug pricing system stands in the way of leading pharmaceutical companies seeking to bring innovative medicines and treatments to Japan.
TAG Managing Partner Kurt Tong Writes About Japan’s Drug Pricing Read More »
Full Paper (English): TAG Paper: Observations on Drug Pricing and Innovation in Japan ENG Full Paper (Japanese): TAG Paper: Observations on Drug Pricing and Innovation in Japan JPN Key Findings As the Government of Japan (GOJ) seeks to re-invigorate Japan’s pharmaceutical industry as a sector for innovation and growth, it can make impactful changes to specific pricing
TAG Paper: Observations on Drug Pricing and Innovation in Japan Read More »
FOR IMMEDIATE RELEASE HANOI, Vietnam; WASHINGTON DC, United States, August 2, 2021 – The Asia Group, LLC (“TAG”), a leading Washington-based strategic advisory firm supporting global businesses and investors across the Indo-Pacific, is proud to announce its efforts as principal strategic and sales advisor to a groundbreaking collaboration and licensed production agreement between Arcturus Therapeutics